Regenxbio (RGNX) Net Equity Issued and Repurchased (2015 - 2017)
Regenxbio's (RGNX) quarterly Net Equity Issued and Repurchased came in at $494000.0 in Q2 2017, down 99.39% quarter-over-quarter from $81.5 million in Q1 2017.
Regenxbio (RGNX) Net Equity Issued and Repurchased (2015 - 2017) Analysis & Trends
Regenxbio's Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $494000.0 for Q2 2017.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $494000.0 in Q2 2017; TTM through Dec 2018 was $494000.0, a 99.4% decrease from a year earlier, with the FY2018 full-year figure at $189.7 million, up 131.38% from the prior year.
- Net Equity Issued and Repurchased retreated to $494000.0 in Q2 2017 per RGNX's latest filing, from $81.5 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $81.5 million in Q1 2017 and bottomed at $494000.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Regenxbio | 528.62 Mn | 298.55 Mn | 21.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 494,000.00 |
| Jun 30, 2017 | 494,000.00 |
| Mar 31, 2017 | 81.50 Mn |
| Mar 31, 2017 | 81.50 Mn |
| Jun 30, 2015 | 41.98 Mn |
| Jun 30, 2015 | 41.98 Mn |
| Mar 31, 2015 | 26.02 Mn |
| Mar 31, 2015 | 26.02 Mn |